Ya. V. Krylova

Ya. V. Krylova

Auto-generated profile, based on publicly available information

Ya. V. Krylova

Regional Clinical Oncology Dispensary, 90 12-go Sentyabrya ul., Ulyanovsk, Russian Federation, 432048

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2024 in Oncohematology
Verified
Journal Article
Open access
PDF file
YKYa. V. Krylova
Ya. V. Krylova
EKE. V. Kondakova
E. V. Kondakova
AGA. N. Gavrilenko
A. N. Gavrilenko
ACA. M. Chekalov
A. M. Chekalov
LFLiudmila Fedorova
Liudmila Fedorova
AKAlexander Kulagin
Alexander Kulagin
Recent advances in the diagnosis and understanding of follicular lymphoma (FL) pathogenesis have had a significant impact on therapeutic tactics. The life expectancy of patients has increased significantly. Currently, the 5-year overall survival of FL patients achieved 90 %, and its median is approaching 20 years. However, FL remains an incurable disease with periods of remission and relapse, requiring multiple therapy courses throughout the patient’s life.The main problem is the treatment of patients with refractory/relapsed forms, especially after 3rd line of therapy, as well as with a primarily resistant course and early (in the first 2 years) relapses. Therefore, despite the indolent FL course in most patients, there remains a need for new drugs that can ensure increased treatment efficacy with minimal toxicity and simultaneously maintain a high quality of life, mainly in the presence of primary refractoriness, early progression and in later lines of therapy. In recent years, new targeted drugs have been studied – phosphoinositide 3-kinase, enhancer of zeste homolog 2 inhibitors, as well as immunological drugs (CAR-T therapy (CAR – chimeric antigen receptor) and bispecific antibodies).The article presents the possibilities of treatment for refractory/relapsed FL as 3rd and subsequent therapy lines.

1 July 2026 in Clinical oncohematology
Verified
Journal Article
Open access
NMNikolai Nikolaevich Mamaev
Nikolai Nikolaevich Mamaev
YKYa. V. Krylova
Ya. V. Krylova
MKM. M. Kanunnikov
M. M. Kanunnikov
ASA. I. Shakirova
A. I. Shakirova
ASA. M. Sadykov
A. M. Sadykov
LZL. S. Zubarovskaya
L. S. Zubarovskaya
Fundamental studies of hematopoiesis have confirmed the existence of WT1-expressing lineage-differentiated hematopoietic precursor cells, which are functionally related with BAALC-expressing hematopoietic stem cells (HSCs), on the one hand, and with WT1-expressing blast elements, on the other. The data obtained provided the basis for analyzing the mixed cohort of patients with CBF-positive and FLT3-mutated variants of acute myeloid leukemia (AML) for developing a panel of molecular markers. The purposes of this panel are therapy efficacy assessment and early diagnosis of relapses alternative to the initial BAALC-expressing HSC clones. The developed combined approach was tested on a big clinical case series including the data from 114 patients with CBF+ (n = 63) and FLT3+ (n = 51) AML variants. The suggested original molecular diagnostic panel based on the serial measurements of BAALC and WT1 expression levels combined with simultaneous determination of the blast content in bone marrow aspirates seems to be a promising and useful tool for both research and clinical practice.

1 October 2026 in Clinical oncohematology
Verified
Journal Article
Open access
PDF file
LBLali Galimovna Babicheva
Lali Galimovna Babicheva
GTG. S. Tumyan
G. S. Tumyan
IPI. V. Poddubnaya
I. V. Poddubnaya
GAG. V. Anisimova
G. V. Anisimova
OAO. Yu. Arzhanukhina
O. Yu. Arzhanukhina
ESE. L. Shemyakina
E. L. Shemyakina
AIM. To assess the efficacy and safety of combined obinutuzumab-based regimens in the first-line therapy for follicular lymphoma (FL) in real-world clinical practice. MATERIALS & METHODS. This retrospective multicenter study enrolled 279 newly diagnosed FL patients treated with obinutuzumab in combination with chemotherapy at 41 medical institutions in Russia from 2018 to 2026. The median age of patients was 49.2 years (range 30–83 years), 60.6 % of them were women. Obinutuzumab-based regimens were predominantly administered to patients with stage III/IV (86.4 %), advanced tumor spread (60.2 %), and often with intraabdominal location (76.3 %). More than 1/3 of patients had extranodal lesions (41.9 %) and bulky tumors (34.8 %). According to FLIPI score, there were 74.9 % of patients with intermediate and poor prognosis. More than half of the patients (54.4 %) received anthracycline-based G-CHOP regimen as initial therapy, GB was administered to 30.1 % of patients. Maintenance therapy with obinutuzumab was used in 72.8 % of cases. RESULTS. Overall response to therapy was achieved in 95.6 % of patients, the rate of complete metabolic response was 91.1 %. Adverse events of any grade were observed in 51.8 % of patients, grade ≥ 3 was identified in 29 % (primarily neutropenia and infectious complications). With the median follow-up of 16.3 months, disease progression or relapse were diagnosed in 21 (7.5 %) patients, histological transformation into diffuse large B-cell lymphoma was reported after 6 out of 14 biopsies performed at the stage of FL relapse. The 2-year progression-free survival was 89.6 %, and the 2-year overall survival was 98 %. CONCLUSION. The results of this study confirm high efficacy of obinutuzumab in the first-line therapy for FL patients with prognostically unfavorable characteristics of tumor. Overall and complete metabolic response rates are consistent with the international data. The administration of obinutuzumab-based regimens provide significant therapeutic control of the disease and confirm the reproducibility of the data from clinical studies in real-world healthcare practice.

10 December 2025 in Oncohematology
Verified
Journal Article
Open access
PDF file
LBLev S. Butaev
Lev S. Butaev
MSM. A. Sannikova
M. A. Sannikova
YKYa. V. Krylova
Ya. V. Krylova
SVS. V. Vlasova
S. V. Vlasova
FBF. E. Babaeva
F. E. Babaeva
VPVadim V. Ptushkin
Vadim V. Ptushkin
Aim. To evaluate the efficacy and safety of mosunetuzumab monotherapy in real clinical practice. Materials and methods. The evaluation of the study results included clinical data from 17 patients with follicular lymphoma (7 women and 10 men) who received mosunetuzumab monotherapy in 4 centers of the Russian Federation from November 9, 2021 to April 3, 2025: Botkin Hospital (11 patients), Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation (4 patients), Yaroslavl Regional Clinical Hospital (1 patient), and the National Medical Research Center for Hematology (1 patient). In the evaluated sample, the majority of patients, 15 (88.2 %) people, had a histological variant of the disease: cytological type follicular lymphoma 1–3A. The median age was 43 (22–61) years. All 17 patients had advanced disease stage (III–IV) according to the Ann Arbor classification at the time of diagnosis. The primary endpoint was the frequency of complete response (percentage of patients) over the entire treatment period. Efficacy criteria: overall response rate (complete and partial response) over the entire treatment period, overall and progression-free survival, as well as safety assessment. Results. The overall response rate was 76.4 % (n = 13). Complete response was achieved in 10 (58.8 %) patients. Disease stabilization was observed in 3 (17.6 %) patients, and disease progression was detected in 1 (5.8 %) patient. The median number of mosunetuzumab courses was 6 (2–17). With a median follow-up of 31 (1–43) months in the patient group, the median progression-free survival and overall survival were not achieved. At 42 months, progression-free and overall survival were 67 and 81 %, respectively. Most of the adverse events were mild (I–II). The most common adverse events were hematological complications: anemia, neutropenia, and thrombocytopenia. Grade III–IV adverse events also included anemia (n = 2 (11.7 %)), thrombocytopenia (n = 3 (17.6 %)), and neutropenia (n = 8 (47.0)). Transfusion of blood components was required in 3 (17.6 %) patients. In 1 (5.8 %) case, an episode of febrile neutropenia was noted. Conclusion. The use of mosunetuzumab in real clinical practice has demonstrated high efficacy and a manageable toxicity profile comparable to published data. The results obtained allow us to consider the use of mosunetuzumab as an alternative treatment regimen for patients with relapsed / refractory follicular lymphoma.